Drugs 'delay breast cancer advance'

Breast cancer experts are hailing what could be some of the biggest advances in more than a decade – two new medicines that significantly delay the time until women with very advanced cases get worse.

In a large international study, an experimental drug from Genentech called pertuzumab held cancer at bay for an average of 18 months when given with standard treatment, as opposed to 12 months for others given only the usual treatment.